Radical mechanism of hydroxyurea side toxicity;Rodnikowy mechanizm ubocznej toksycznos̈ci hydroksymocznika

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 516-526

  Przybyszewski, Waldemar M ^a   Kasperczyk, Janusz ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Katedra i Zak ad Biofarmacji   (Poland)

Author keywords

Erythrocytes; Free radicals; Granulocytes; Hydroxyurea; Lipid peroxidation; Lysosomes; Unbalanced growth

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; DNA; HYDROXYUREA; SCAVENGER;

CELL DEATH; CELL DIVISION; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE; OSMOTIC FRAGILITY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL DEATH; CELL DIVISION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FREE RADICAL SCAVENGERS; HYDROXYUREA; OSMOTIC FRAGILITY;

EID: 39049180304     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Agrawal A., Kale R.K.: Radiation induced peroxidative damage: mechanism and significance. Indian J. Exp. Biol., 2001; 39: 291-309
2. Akeson S.P., Mel H.C.: Osmotic hemolysis and fragility. A novel model based on membrane disruption, and a potential clinical test. Biochem. Biophys. Acta, 1982; 718: 201-211
3. Anand S., Verma H., Kumar L., Singh N.: Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin. Cancer Lett., 1995; 88: 101-105
4. Belt R.J., Haas C.D., Kennedy J., Taylor S.: Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer, 1980; 46: 455-462
5. Bienvenu P., Caron L., Gasparutto D., Kergonou J.F.: Assessing and counteracting the prooxidant effects of anticancer drugs. EXS, 1992; 62: 257-265
6. Blume R.S., Glade P.R., Chessin L.N.: Euchrisine, a supravital fluorescent lysosomal stain: technics and application for hematologic investigation. Blood, 1969; 33: 87-99
7. Boyd A.S., Neldner K.H.: Hydroxyurea therapy. J. Am. Acad. Dermatol., 1991; 25: 518-524
8. Cheung A.Y., Browne B., Capen C.: Hydroxyurea induced fever in cervical carcinoma: case report and review of the literaturte. Cancer Invest., 1999; 17: 245-248
9. Clemens M.R., Remmer H.: Volatile alkanes produced by erythrocytes: an assay for in vitro studies on lipid peroxidation. Blut, 1982; 45: 329-335
10. Conklin K.A.: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther., 2004; 3: 294-300
11. Conklin K.A.: Dietary antioxidants during cancer chemotheraopy: impact on chemotherapeutic effectiveness and development of side effects. Nutr. Cancer, 2000; 37: 1-18
12. Conklin K.A.: Cancer chemotherapy and antioxidants. J. Nutr., 2004; 134: 3201S-3204S
13. DeSesso J.M.: Cell death and free radicals: A mechanism for hydroxyurea teratogenesis. Med. Hypotheses, 1979; 5: 937-951
14. Frearson P.M., Kit S., Dubbs D.R.: Induction of dihydrofolate reductase activity by SV40 and polyoma virus. Cancer Res.,1966; 26: 1653-1660
15. Grabarczyk M., Przybyszewski W.M., Kwiatkowska J., Sitarska E., Malec J.: Alteration in lysosome supravital staining as a marker of hydroxyurea-induced cytotoxicity and its modification by radical scavengers in L5178Y cells in culture. Neoplasma, 1983; 30: 541-545
16. Gui C.Y., Jiang C., Xie H.Y., Qian R.L.: The apoptosis of HEL cells induced by hydroxyurea. Cell Res., 1997; 7: 91-97
17. Hanft V.N., Fruchtman S.R., Pickens C.V., Rosse W.F., Howard T.A., Ware R.E.: Acquire DNA mutations associated with in vivo hydroxyurea exposure. Blood, 2000; 95: 3589-3593
18. Horvat A., Acs G.: Induction of lysosomal enzymes in contact inhibited 3T3 cells. J. Cell Physiol., 1974; 83: 59-68
19. Huyghe P., Dassonneville L., Fenaux P., Bailly C.: Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line. Oncol. Res., 2004; 14: 235-245
20. Janero D.R.: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med., 1990; 9: 515-540
21. Jiang J., Jordan S.J., Barr D.P., Gunther M.R., Maeda H., Mason R.P.: In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol. Pharmacol., 1997; 52: 1081-1086
22. King S.B.: Nitric oxide production from hydroxyurea. Free Radic. Biol. Med., 2004; 37: 737-744
23. Kinsella T.J.: Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizers. Semin. Oncol., 1992; 19 (3 Suppl.9): 41-47
24. Kit S., DeTorres R.A., Dubbs D.R.: Arabinofuranosylcytosine-induced stimulation of thymidine kinase and deoxycytydilic deaminase activities of mammalian cultures. Cancer Res.,1966; 26: 1859-1866
25. Klein-Szanto A.J., de Rey B.L., Conti C.J., Cabrini R.L.: Ultrastructure of irradiated nuclei. Strahlentherapie, 1974; 147: 263-270
26. Kondakova I.V., Zagrebelnaya G.V., Choinzonov E.T.: NO-generating compounds modify tumoritoxic effect of doxorubicin. Bull. Exp. Biol. Med., 2004; 137: 585-587
27. Li V., Kelly K., Schrot R., Langan T.J.: Cell cycle kinetics and commitment in newborn, adult, and tumoral astrocytes. Brain Res. Dev. Brain Res., 1996; 96: 138-147
28. Lieberman M.W., Verbin R.S., Landay M., Liang H., Farber E., Lee T.N., Starr R.: A probable role for protein synthesis in intestinal epithelial cell damage induced in vivo by cytosine arabinoside, nitrogen mustard or X-irradiation. Cancer Res., 1970; 30: 942-951
29. Malec J., Przybyszewski W.M., Grabarczyk M., Sitarska E.: Hydroxyurea has the capacity to induce damage to human erythrocytes which can be modified by radical scavegers. Biochem. Biophys. Res. Commun., 1984; 120: 566-573
30. Malec J., Przybyszewski W.M., Grabarczyk M., Sitarska E., Czartoryska B.: Mechanism of unbalanced growth-induced cell damage. I. A probable role for hydrolytic enzymes synthesis. Chem. Biol. Interact., 1986; 57: 315-324
31. Malec J., Przybyszewski W.M., Szczepañska I., Sitarska E., Zdziechowska H., Pawelski S.: Preliminary trials of the modification of toxic side effects in patients after administration of Hydroxyurea-Cytosar-Rubidomycin. Tschechoslovak-German-Polish Trilateral Meeting. Zakopane. 1984; Abstracts: 85
32. Malec J., Szczepañska I., Grabarczyk M., Przybyszewski W.M., Kopeæ-Szlêzk J., Sitarska E.: Hydroxyurea-induced toxic side-effects in animals and an attempt at reducing them with vitamins E and C. Neoplasma, 1989; 36: 427-435
33. Maridonneau I., Braquet P., Garay R.P.: Na+ and K+ transport damage induced by oxygen free radicals in human red cell membranes. J. Biol. Chem., 1983; 258: 3107-3113
34. Meneghini R., Hoffmann M.E.: The damaging action of hydrogen peroxide on DNA of human fibroblasts is mediated by a non-dialyzable compound. Biochem. Biophys. Acta, 1980; 608: 167-173
35. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L.: Anthracyclines: Molecular and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev., 2004; 56: 185-229
36. Mitcher J.S., Shelbourne J.D., Bradford N.D., Hawkins H.K.: Cellular autophagocytosis induced by deprivation of serum and aminoacids in HeLa cells. Am. J. Pathol., 1976; 83: 485-489
37. Moore E.C., Hurlbert R.B.: The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Pharmacol. Ther., 1985; 27: 167-196
38. Navarra P., Preziosi P.: Hydroxyurea: new insight on an old drug. Critic. Rev. Oncol. Hematol., 1999; 29: 249-255
39. Orringer E.P., Parker J.C.: Hydroxyurea and sickle cell disease. Hematol. Pathol., 1992; 6: 171-178
40. Painter R.B.: Rapid test to detect agents that damage human DNA. Nature, 1977; 265: 650-651
41. Przybyszewski W.M.: Kompleks reduktazy rybonukleotydowej. Post. Biochem., 1983; 29: 321-333
42. Przybyszewski W.M.: Udzial produktów peroksydacji lipidów w przeciwnowotworowym mechanizmie dzialania promieniowania jonizujacego i cytostatyków radiomimetycznych. Post. Hig. Med. Dosw., 2001; 55: 803-813
43. Przybyszewski W.M., Czartoryska B., Malec J.: Effect of hydroxyurea treatment on lysosomal membrane stability and enzyme latency in L5178Y cells in culture. Neoplasma, 1986; 33: 27-31
44. Przybyszewski W.M., Kopeæ-Szlêzak J., Malec J.: Protection of L5178Y cells by Vitamin E against acute hydroxyurea toxicity does not change the efficiency of ribonucleotide reductase-mediated hydroxyureainduced cytotoxic events. Cancer Lett., 1987; 34: 337-344
45. Przybyszewski W.M., Malec J.: Molekularne i komórkowe efekty dzialania hydroksymocznika. Post. Biochem., 1982; 28: 353-372
46. Przybyszewski W.M., Malec J.: Hydroxyurea, methotrexate and adriblastine can mediate non-enzymatic reduction of nitroblue tetrazolium with NADH which is inhibited by superoxide dismutase. Biochem. Pharmacol., 1987; 36: 3312-3314
47. Przybyszewski W.M., Malec J.: Protection against hydroxyurea-induced cytotoxic effects in L5178Y cells by free radical scavengers. Cancer Lett., 1982; 17: 223-228
48. Ravandi-Kashani F., Cortes J., Cohen P., Talpaz M., O'Brien S., Markowitz A., Kantarjian H.: Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk. Lymphoma, 1999; 35: 109-118
49. Ross D.W.: The nature of unbalanced cell growth caused by cytotoxic agents. Virchovs Arch. B. Cell. Pathol. Incl. Mol. Pathol., 1981; 37: 225-235
50. Ross D.W.: Cell volume growth after cell cycle block with chemotherapeutic agents. Cell Tissue Kinet., 1976; 9: 379-387
51. Ross D.W.: Unbalanced cell growth and increased protein synthesis induced by chemotherapeutic agents. Blood Cells, 1983; 9: 57-68
52. Roy B., Guittet O., Beuneu C., Lemaire G., Lepoivre M.: Depletion of deoxyribonucleotide triphosphate pools in tumor cells by nitric oxide. Free Radic. Biol. Med., 2004; 36: 507-516
53. Saha B.K., Sameshima M., Sameshima F., Schlessinger D.: Lysosomal enzyme activities and RNA turnover rates in growing and nongrowing WI-38 and HeLa cells. In Vitro, 1981; 17: 816-824
54. Sakano K., Oikawa S., Hasegawa K., Kawanishi S.: Hydroxyurea induces site-specific DNA damage via formation hydrogen peroxide and nitric oxide. Jpn. J. Cancer Res., 2001; 92: 1166-1174
55. Sawecka J., Golos B., Malec J.: Mechanism of unbalanced growthinduced cell damage II. A probable relationship between unbalanced growth, DNA breakage and cell death. Chem. Biol. Interact., 1986; 60: 47-55
56. Singal P.K., Siveski-Iliskovic N., Hill M., Thomas T.P., Li T.: Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell. Cardiol., 1995; 27: 1055-1063
57. Siveski-Iliskovic N., Hill M., Chow D.A., Singal P.K.: Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 1995; 91: 10-15
58. Stevens M.R.: Hydroxyurea: an overview. J. Biol. Regul. Homeost. Agents, 1999; 13: 172-175
59. Stocks J., Dormandy T.L.: The autooxidation of human red cell lipids induced by hydrogen peroxide. Br. J. Haematol., 1971; 20: 95-111
60. Stocks J., Dormandy T.L.: A direct thiobarbituric acid-reacting chromogen in human red blood cells. Clin. Chim. Acta, 1970; 27: 117-120
61. Stubblefield E., Mueller G.C.: Thymidine kinase activity in synchronized HeLa cell cultures. Biochem. Biophys. Res. Commun.,1965; 20: 535-538
62. Studzinski G.P., Cohen L.S.: Mitomycin C-induced increase in the activities of the deoxyribonucleases of HeLa cells. Biochem. Biophys. Res. Commun., 1966; 23: 506-512
63. Szczepañska I., Kwiatkowska J., Przybyszewski W.M., Sitarska E., Malec J.: Amelioration of hydroxyurea-induced suppression of phagocytosis in human granulocytes by free radical scavengers. Scand. J. Haematol., 1985; 34: 35-38
64. Tappel A.L.: Lipid peroxidation damage to cell components. Fed. Proc., 1973; 32: 1870-1874
65. Timson J.: Hydroxyurea. Mutation Res., 1975; 32: 115-132
66. Tyan M.L.: Age-related increase in erythrocyte oxidant sensitivity. Mech. Ageing Dev., 1982; 20: 25-32
67. Vadlamundi S., Krishna B., Reddy V.S., Goldin A.: Schedule dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic L5178Y mice. Cancer Res., 1973; 33: 2014-2019
68. Valerius N.H., Johansen K.S., Nelsen S., Platz P., Rosenkvist J., Sorensen H.: Effect of in vitro X-irradiation on lymphocyte and granulocyte function. Scand. J. Haematol., 1981; 27: 9-18
69. Wadler S., Hayes H., Schechner R., Rozenblit A., Wiernik P.H.: Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies. Invest. New Drugs, 1996; 13: 315-320
70. Wills E.D., Wilkinson A.E.: Release of enzymes from lysosomes by irradiation and the relation of lipid peroxide formation to enzyme release. Biochem. J., 1966; 99: 657-666
71. Whittaker J.A., Hughes H.N., Khurshid H.: The effect of cytotoxic and antiinflamatory drugs on the phagocytosis of neutrophil leukocytes. Br. J. Haematol., 1975; 29: 273-279
72. Yarbro J.W.: Mechanism of action of hydroxyurea. Semin. Oncol., 1992; 19 (3 Suppl.9): 1-10
73. Zhao M., Antunes F., Eaton J.W., Brunk U.T.: Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur. J. Biochem., 2003; 270: 3778-3786